News
OPORF
0.350
NaN%
--
hVIVO Showcases Integrated Early-Stage Drug Development Platform at Capital Markets Day
TipRanks · 1d ago
hVIVO Shareholders Back All Resolutions at Annual General Meeting
TipRanks · 05/13 12:41
Stifel Nicolaus Remains a Hold on Open Orphan Plc (HVO)
TipRanks · 05/07 17:05
hVIVO wins £6m influenza human challenge trial to test monoclonal antibody
TipRanks · 05/07 06:24
hVIVO Director Brendan Buckley Sells Shares Ahead of Board Exit
TipRanks · 04/24 17:17
Shore Capital Sticks to Their Buy Rating for Open Orphan Plc (HVO)
TipRanks · 04/23 03:15
hVIVO Wins Landmark Phase III Human Challenge Contract for ILiAD’s Whooping Cough Vaccine
TipRanks · 04/22 06:26
hVIVO Publishes 2025 Annual Report and Sets May AGM Date
TipRanks · 04/17 06:10
Open Orphan Plc Earnings Call: Diversifying Amid Strain
TipRanks · 04/17 00:04
Stifel Nicolaus Keeps Their Hold Rating on Open Orphan Plc (HVO)
TipRanks · 04/15 21:05
hVIVO Reshapes Clinical Platform as 2025 Profits Slide on Sector Headwinds
TipRanks · 04/15 06:14
hVIVO Rebrands as Unified End-to-End Clinical Development Partner
TipRanks · 04/14 06:48
hVIVO seals Traws Pharma deal for Phase 2a influenza human challenge trial
TipRanks · 04/14 06:15
hVIVO sets 15 April date to unveil 2025 final results
TipRanks · 04/07 06:07
hVIVO Issues New Shares as Part of Cryostore Acquisition
TipRanks · 02/23 07:09
Open Orphan Plc (HVO) Gets a Buy from Shore Capital
TipRanks · 01/29 16:36
hVIVO upgraded to Buy from Add at Peel Hunt
TipRanks · 01/29 09:55
hVIVO Beats EBITDA Guidance as Acquisitions Cement Full-Service CRO Platform
TipRanks · 01/29 07:24
hVIVO Sets Date for 2025 Trading Update and Investor Presentation
TipRanks · 01/27 07:07
hVIVO Bolsters Board with Appointment of Richard Cotton as Non-Executive Director
TipRanks · 12/18/2025 07:08
More
Webull provides a variety of real-time OPORF stock news. You can receive the latest news about Hvivo through multiple platforms. This information may help you make smarter investment decisions.
About OPORF
hVIVO plc is a United Kingdom-based specialist early-stage drug development contract research organization (CRO) and human challenge trials. The Company delivers end-to-end clinical development services to a diverse and expanding client base. It specializes in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its quarantine facility. The Company also offers comprehensive virology and immunology laboratory services under the hLAB brand. The Company, through its subsidiary, operates an approximately 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. It also offers Early Drug Development Consulting and Biometry services to the biopharma sector. The Company also provides industry-standard, temperature-controlled storage solutions for biological and clinical materials.